Revvity, Inc. (NYSE: RVTY), a provider of health science solutions and technologies, on Monday reported an increase in revenue and adjusted profit for the first quarter of 2025.
- Revvity reported revenue of $665 million for the March quarter, compared to $650 million in the same period a year ago
- In the Life Sciences segment, revenue and organic revenue increased 1% and 2%, respectively, during the three months
- Diagnostic revenue moved up 3% YoY in Q1, Diagnostic organic revenue increased by 5%
- Reported earnings, on a per-share basis, increased to $0.35 in the first quarter from $0.21 in the prior-year period
- Adjusted earnings from continuing operations were $1.01 per share in Q1, vs. $0.98 per share in the first quarter of 2024
- Operating profit margin from continuing operations was 10.9% as a percentage of revenue, compared to 6.8% in the year-ago quarter
- The company raised its full-year revenue guidance to a range of $2.83-$2.87 billion, reflecting recent changes in foreign currency exchange rates
- It reaffirmed its adjusted earnings per share guidance in the range of $4.90 and $5.00